Figure 9.
Hematology and clinical chemistry observed at 85 d following treatment with either (A) single cycle of anti-HER2-DOTA-PRIT + 55.5 MBq of 177Lu-DOTA-Bn (total activity: 55.5 MBq/mouse) or (B) fractionated three-cycle treatment of anti-HER2-DOTA-PRIT + 55.5 MBq of 177Lu-DOTA-Bn (total activity: 167 MBq/mouse). The range of values for the animals given no treatment is shaded in grey for reference.